rood blauwe elepsis logo Belegger.nl
Uitgebreid zoeken

Guru Terug naar discussie overzicht

***** GNBT *******

3.572 Posts
Pagina: «« 1 ... 146 147 148 149 150 ... 179 »» | Laatste | Omlaag ↓
  4. [verwijderd] 17 juli 2007 15:37

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    officiele lancering fase III zal toch ook eerdaags moeten komen, gezien generx nog in H2 dit wil straten...en daar aan voorafgaand aankondiging afsluiting fase II...

    zal de koers zeker heel goed doen :)
  9. [verwijderd] 23 juli 2007 15:36

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    rt 1.72

    keors is al weken lang stabile rond deze koers. Het lijkt er op dat de shorters steeds minder invloed krijgen, en plaats maken voor instituten.
    Tis nu wachten op volgende upswing :)

    eerdaags...
  14. [verwijderd] 25 juli 2007 09:46

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Generex Biotechnology Corporation Announces Prestigious National Award Received by Clinical Investigator Who Has Done Extensive Work On Generex Oral-lyn

    Tuesday, July 24, 2007




    WORCESTER, Mass., July 24, 2007 (PRIME NEWSWIRE) -- Generex Biotechnology Corporation (NasdaqCM:GNBT - News), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced today that Dr. Jaime Guevara-Aguirre was recently awarded the Vicente Rocafuerte Award for Scientific Merit. The top honor was granted to Dr. Guevara-Aguirre by the National Congress of Ecuador.

    The determining factors, according to the Medical and Scientific Commission of the National Congress of Ecuador, were Dr. Guevara-Aguirre's research and clinical work in Generex Oral-lyn(tm) and Laron syndrome.

    Dr. Jaime Guevara was the first clinician to conduct human clinical trials on Generex Oral-lyn(tm) back in 1995 and since then had conducted numerous trials of Generex Oral-lyn(tm) with both Type 1 and Type 2 patients. Some of his trials assisted in establishing the dosing regiment for Generex Oral-lyn(tm) which have been incorporated in the company's Phase III protocol for global trials.

    ``We are pleased that a clinician who has devoted much clinical work towards Generex Oral-lyn(tm) was bestowed with the highest medical and scientific honour of his country,'' says Anna Gluskin, Generex's President and CEO. ``The fact that Dr. Jaime Guevara-Aguirre was recognized specifically for his work towards Generex Oral-lyn(tm) signifies that governmental bodies and agencies are starting to recognize the importance that Generex Oral-lyn(tm) will play in the treatment of diabetes.''

  19. [verwijderd] 26 juli 2007 09:43

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Dat klopt

    Ik ben weer terug


    Heerlijke vakantie gehad.

    GNBT redelijk stabiel gebleven .

    Ze hebben op mijn terugkomst gewacht voor de grote stijging gaat beginnen .
    hoppaaaaaaa
  20. [verwijderd] 26 juli 2007 09:44

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    NA BEURS persbericht !

    Generex Biotechnology Announces Expansion of Retail Chains -- Including Key Online Storefronts -- Carrying Glucose RapidSpray

    Wednesday, July 25, 2007




    WORCESTER, Mass., July 25, 2007 (PRIME NEWSWIRE) -- Generex Biotechnology Corporation (NasdaqCM:GNBT - News), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced today that the number of retail chains in Canada and the United States that are presently carrying its proprietary Glucose RapidSpray(tm) product has expanded. The latest addition to the retail chains have been a number of key online storefronts including www.Amazon.com and www.Walgreens.com; the first online storefront to carry the product was www.DiabeticExpress.com
    Presently, Glucose RapidSpray (http://www.GlucoseRapidSpray.com) is being marketed in the United States and Canada through a number of leading retail chains. Amongst them are Amerimark Direct, Butler Drug Store, DIK Drug Co., Fruth Pharmacy, H.D. Smith Wholesale Drug, Hy-Vee Inc., Kerr Drug Inc., Kinney Drug, Inc., Kinray Inc., Meijer, Smith Drug Company, ShopKo, Weiss Markets Inc., Value Drug Company, RDC, Aurora Pharmacy, Amerisource Bergen, Bainder International Drug Stores, McKesson Drug Company, Cardinal Health Pharmacies, Amerisource Bergen, Kohl & Frisch Limited, Shoppers Drug Mart and UniPharm Wholesale Drugs Ltd.

    Glucose RapidSpray is also being marketed in the Middle East through its Master Distributor Leosons General Trading Company.

    Glucose RapidSpray is an innovative alternative for people who want additional glucose in their diet. The product delivers a fat-free, low-calorie glucose formulation directly into the buccal cavity using the Company's proprietary buccal drug delivery technologies. Glucose RapidSpray is simple to carry and use.

    ``We are pleased to expand the marketing and distribution of Glucose RapidSpray to additional retail chains with multiple locations,'' says Rose C. Perri, Generex's Chief Operating Officer. ``We recognize the importance of the e-commerce market and we are pleased to have the opportunity to distribute within this marketplace as well. We look forward to exploring all of the commercial and marketing avenues available.''

    About Generex

    Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(tm) device. The Company's flagship product, oral insulin (Generex Oral-lyn(tm)), which is available for sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes and before the end of 2007 the Company expects to begin Phase 3 trials of the product in the United States, Canada and Europe. For more information, visit the Generex website at www.generex.com.

    Safe Harbor Statement: This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain ``forward-looking statements'' within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as ``expects,'' ``plans,'' ``intends,'' ``believes,'' ``will,'' ``estimates,'' ``forecasts,'' ``projects'' or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any ``phase'' of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.



    Contact:
    Generex Biotechnology Corporation
    Shayne Gilliatt
    800-391-6755
    416-364-2551

    CEOcast, Inc.
    Andrew Hellman
    212-732-4300


    hoppaaaaaaa
  21. [verwijderd] 26 juli 2007 09:51

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    regeren is vooruitzien .

    De markt voor GNBT produkten gaat explosief stijgen


    Kijk wat er alleen al in Nederland te wachten staat met de stijging van het aantal diabetici !!!!!!!!!!!!
    Ken je nagaan wat een aantallen het gaan worden over de hele wereld .

    Gewoon GNBT kopen en heel lang vasthouden .


    http://www.nu.nl/news/1170745/83/Steeds_meer_chronisch_zieken.html
    Steeds meer chronisch zieken
    Uitgegeven: 26 juli 2007 08:48
    Laatst gewijzigd: 26 juli 2007 08:49

    AMSTERDAM - Het aantal chronisch zieken neemt de komende twintig jaar 'flink' toe. Naar verwachting hebben in 2025 bijna een miljoen suikerpatiënten, 540 duizend mensen een chronische longziekte en 1,2 miljoen mensen osteoporose.

    Dat meldt het Rijksinstituut voor Volksgezondheid en Milieu (RIVM) donderdag op basis van onderzoek.


    Ook het aantal hart- en vaatziekten neemt toe van 1 tot 1,5 miljoen. Het RIVM noemt de vergrijzing als hoofdoorzaak, maar ook ongezond gedrag speelt volgens het instituut een belangrijke rol.

    Het aantal mensen met suikerziekte stijgt met zeventig procent naar 940 duizend in 2025. Dat is het geval wanneer de huidige stijging in het aantal mensen met overgewicht in hetzelfde tempo doorzet. Wanneer de stijging in overgewicht toeneemt, kan het aantal suikerpatiënten aantal boven een miljoen uitkomen.

    Roken

    Ziekten die samenhangen met roken, nemen bij mannen minder sterk toe dan in het verleden. Bij vrouwen nemen ze juist sterker toe. Mannen zijn de laatste jaren minder gaan roken, vrouwen juist meer.

    (c) Novum

    hoppaaaaaaa
3.572 Posts
Pagina: «« 1 ... 146 147 148 149 150 ... 179 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Belegger.nl

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.017
AB InBev 2 5.499
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 51.665
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 265
Accsys Technologies 23 10.667
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 189
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.752
Aedifica 3 916
Aegon 3.258 322.845
AFC Ajax 538 7.088
Affimed NV 2 6.297
ageas 5.844 109.893
Agfa-Gevaert 14 2.050
Ahold 3.538 74.337
Air France - KLM 1.025 35.045
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.041
Alfen 16 24.851
Allfunds Group 4 1.473
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 406
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.822
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 243.228
AMG 971 133.349
AMS 3 73
Amsterdam Commodities 305 6.690
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 491
Antonov 22.632 153.605
Aperam 92 15.007
Apollo Alternative Assets 1 17
Apple 5 382
Arcadis 252 8.776
Arcelor Mittal 2.033 320.712
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.302
Aroundtown SA 1 219
Arrowhead Research 5 9.739
Ascencio 1 28
ASIT biotech 2 697
ASMI 4.108 39.108
ASML 1.766 107.394
ASR Nederland 21 4.486
ATAI Life Sciences 1 7
Atenor Group 1 491
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.673
Axsome Therapeutics 1 177
Azelis Group 1 64
Azerion 7 3.392